Topiramate extended-release - Supernus Pharmaceuticals

Drug Profile

Topiramate extended-release - Supernus Pharmaceuticals

Alternative Names: SPN-538; Topiramate controlled-release - Supernus Pharmaceuticals; TPM XR; Trokendi XR; Trokesa

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Epilepsy
  • Preregistration Migraine

Most Recent Events

  • 19 Aug 2016 The US FDA grants tentative approval for Topiramate extended release for treatment of Migraine (Prevention) in USA
  • 15 Mar 2016 Biomarkers information updated
  • 26 Feb 2016 Aequus Pharmaceuticals plans to launch Topiramate extended release in Canada in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top